PMN Profile
ProMIS Neurosciences, Inc., headquartered in Toronto, Canada, is a biopharmaceutical company specializing in the discovery and development of precision medicine for neurodegenerative diseases. The company's innovative approach targets complex neurological conditions, including Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). Established in 2004 as Amorfix Life Sciences Ltd., ProMIS rebranded to its current name in July 2015 to better reflect its focus on precision neuroscience.
ProMIS Neurosciences employs its proprietary discovery platform, which integrates the ProMIS and Collective Coordinates algorithms, to identify novel therapeutic targets. These algorithms are designed to predict disease-specific epitopesâ€unique molecular surfaces on misfolded proteins that are associated with neurodegenerative diseases. This approach enables the development of highly targeted therapies aimed at addressing the underlying mechanisms of these conditions.
The company’s lead product candidates include PMN310, a monoclonal antibody (mAb) that targets toxic oligomers involved in Alzheimer's disease. Another key candidate, PMN267, is designed to address multiple neurodegenerative targets, including superoxide dismutase 1 and TAR-DNA binding protein 43 in ALS, as well as alpha-synuclein in Parkinson’s disease and Lewy body dementia. Additionally, PMN442 is an mAb aimed at targeting toxic alpha-synuclein oligomers and seeding fibrils in MSA, a rare but severe neurodegenerative disorder.
ProMIS Neurosciences continues to advance its pipeline with the goal of delivering breakthrough treatments for neurodegenerative diseases, leveraging its precision medicine platform to offer novel and effective solutions. With a focus on addressing unmet medical needs in neurology, the company remains committed to advancing research and development efforts to improve the lives of patients suffering from these debilitating conditions.
|
